MedTrace Logo

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2020-08-07

No results posted yet for this study

Summary

Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.

Conditions

Interventions

DRUG

ASA plus Clopidogrel

OAC (6 weeks) + DAPT (until 6 months) + ASA

DRUG

Genetic-Tailored AntiThrombotic Strategy

Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype

DRUG

Half-Dose of novel OAC

Half Dose of novel OAC post-device Implantation

Sponsors & Collaborators

  • Texas Cardiac Arrhythmia Research Foundation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04502017 on ClinicalTrials.gov